Non-coding RNAs in renal cell carcinoma: Implications for drug resistance

被引：6
作者：
Liu, Yiqi [1 ]
Zhang, Hu [2 ]
Fang, Yuan [3 ]
Tang, Dongshan [4 ]
Luo, Zhigang [5 ]
机构：
[1] Univ South China, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China
[2] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Urol, Hengyang 421001, Hunan, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Organ Transplantat Ctr, Kunming 650032, Yunnan, Peoples R China
[4] Univ South China, Sch Resources & Environm & Safety Engn, Hengyang 421001, Hunan, Peoples R China
[5] Univ South China, Affiliated Hosp 2, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 164卷
关键词：
Renal cell carcinoma; Drug resistance; Non -coding RNAs; Biomarkers; MiRNAs; SUNITINIB RESISTANCE; TUMOR PROGRESSION; CIRCULAR RNAS; BREAST-CANCER; TUMORIGENESIS; CHEMORESISTANCE; TRANSCRIPTION; ANGIOGENESIS; METASTASIS; INHIBITION;
D O I：
10.1016/j.biopha.2023.115001
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Renal cell carcinoma (RCC) represents a malignant tumor of the urinary system. Individuals with early-stage RCC could be cured by surgical treatment, but a considerable number of cases of advanced RCC progress to drug resistance. Recently, numerous reports have demonstrated that a variety of non-coding RNAs (ncRNAs) contribute to tumor occurrence and development. ncRNAs can act as oncogenic or tumor suppressor genes to regulate proliferation, migration, drug resistance and other processes in RCC cells through a variety of signaling pathways. Considering the lack of treatment options for advanced RCC after drug resistance, ncRNAs may be a good choice as biomarkers of drug resistance in RCC and targets to overcome drug resistance. In this review, we discussed the effects of ncRNAs on drug resistance in RCC and the great potential of ncRNAs as a biomarker of or a new therapeutic method in RCC.
引用
收藏
页数：10
相关论文
共 128 条
  • [1] The non-coding RNA interactome in joint health and disease
    Ali, Shabana A.
    Peffers, Mandy J.
    Ormseth, Michelle J.
    Jurisica, Igor
    Kapoor, Mohit
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2021, 17 (11) : 692 - 705
  • [2] From genotype to phenotype: genetics of mammalian long non-coding RNAs in vivo
    Andergassen, Daniel
    Rinn, John L.
    [J]. NATURE REVIEWS GENETICS, 2022, 23 (04) : 229 - 243
  • [3] HOTAIR and androgen receptor synergistically increase GLI2 transcription to promote tumor angiogenesis and cancer stemness in renal cell carcinoma
    Bai, Ji-Yu
    Jin, Ben
    Ma, Jian-Bin
    Liu, Tian-Jie
    Yang, Chao
    Chong, Yue
    Wang, Xinyang
    He, Dalin
    Guo, Peng
    [J]. CANCER LETTERS, 2021, 498 : 70 - 79
  • [4] Treatment of renal cell carcinoma: Current status and future directions
    Barata, Pedro C.
    Rini, Brian I.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) : 507 - 524
  • [5] The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics
    Bautista-Sanchez, Diana
    Arriaga-Canon, Cristian
    Pedroza-Torres, Abraham
    De La Rosa-Velazquez, Inti Alberto
    Gonzalez-Barrios, Rodrigo
    Contreras-Espinosa, Laura
    Montiel-Manriquez, Rogelio
    Castro-Hernandez, Clementina
    Fragoso-Ontiveros, Veronica
    Maria Alvarez-Gomez, Rosa
    Herrera, Luis A.
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 20 : 409 - 420
  • [6] Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma
    Bedke, Jens
    Albiges, Laurence
    Capitanio, Umberto
    Giles, Rachel H.
    Hora, Milan
    Lam, Thomas B.
    Ljungberg, Borje
    Marconi, Lorenzo
    Klatte, Tobias
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Fernandez-Pello, Sergio
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Powles, Thomas
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2021, 79 (03) : 339 - 342
  • [7] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
    Bi, Kevin
    He, Meng Xiao
    Bakouny, Ziad
    Kanodia, Abhay
    Napolitano, Sara
    Wu, Jingyi
    Grimaldi, Grace
    Braun, David A.
    Cuoco, Michael S.
    Mayorga, Angie
    DelloStritto, Laura
    Bouchard, Gabrielle
    Steinharter, John
    Tewari, Alok K.
    Vokes, Natalie, I
    Shannon, Erin
    Sun, Maxine
    Park, Jihye
    Chang, Steven L.
    McGregor, Bradley A.
    Haq, Rizwan
    Denize, Thomas
    Signoretti, Sabina
    Guerriero, Jennifer L.
    Vigneau, Sebastien
    Rozenblatt-Rosen, Orit
    Rotem, Asaf
    Regev, Aviv
    Choueiri, Toni K.
    Van Allen, Eliezer M.
    [J]. CANCER CELL, 2021, 39 (05) : 649 - +
  • [8] A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
    Bin Riaz, Irbaz
    He, Huan
    Ryu, Alexander J.
    Siddiqi, Rabbia
    Naqvi, Syed Arsalan Ahmed
    Yao, Yuan
    Husnain, Muhammad
    Narasimhulu, Deepa Maheswari
    Mathew, Jessey
    Sipra, Qurat Ul Ain Riaz
    Vandvik, Per Olav
    Joseph, Richard W.
    Liu, Hongfang
    Wang, Zhen
    Herasevich, Vitaly
    Singh, Parminder
    Hussain, Syed A.
    Ho, Thai H.
    Bryce, Alan H.
    Pagliaro, Lance C.
    Murad, Mohammad H.
    Costello, Brian A.
    [J]. EUROPEAN UROLOGY, 2021, 80 (06) : 712 - 723
  • [9] Immunotherapeutic strategies in kidney cancer - when TKIs are not enough
    Biswas, Swethajit
    Eisen, Tim
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) : 478 - 487
  • [10] Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma
    Braun, David A.
    Bakouny, Ziad
    Hirsch, Laure
    Flippot, Ronan
    Van Allen, Eliezer M.
    Wu, Catherine J.
    Choueiri, Toni K.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (04) : 199 - 214
12345678910